Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGiles, C.en
dc.contributor.authorNdi, O.en
dc.contributor.authorBarton, M.en
dc.contributor.authorVanniasinkam, T.en
dc.identifier.citationPloS one, 2016; 11(3):1-15en
dc.description.abstractRhodococcus equi is a respiratory pathogen which primarily infects foals and is endemic on farms around the world with 50% mortality and 80% morbidity in affected foals. Unless detected early and treated appropriately the disease can be fatal. Currently, there is no vaccine available to prevent this disease. For decades researchers have endeavoured to develop an effective vaccine to no avail. In this study a novel human adenoviral vector vaccine for R. equi was developed and tested in the mouse model. This vaccine generated a strong antibody and cytokine response and clearance of R. equi was demonstrated following challenge. These results show that this vaccine could potentially be developed further for use as a vaccine to prevent R. equi disease in foals.en
dc.description.statementofresponsibilityCarla Giles, Olasumbo Ndi, Mary D. Barton, Thiru Vanniasinkamen
dc.publisherPloS Oneen
dc.rights© 2016 Giles et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.subjectLung; Animals; Mice, Inbred C3H; Horses; Mice; Rhodococcus equi; Actinomycetales Infections; Horse Diseases; Bacterial Vaccines; Antibodies, Bacterial; Cytokines; Enzyme-Linked Immunosorbent Assay; Femaleen
dc.titleAn adenoviral vector based vaccine for Rhodococcus equien
dc.typeJournal articleen
pubs.library.collectionZoology publicationsen
Appears in Collections:Zoology publications

Files in This Item:
File Description SizeFormat 
hdl_107152.pdfPublished Version2.69 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.